This review summarizes the results of several pharmacological interventions that have been
evaluated in the management of acute myocardial infarction. Of these, thrombolytic therapy …

Acute myocardial infarction is a common cause of death. Most of the deaths are due to
ventricular fibrillation occurring soon after the onset of ischaemia. Once the patient reaches …

In recent years, several large randomized trials have clarified the role of various
interventions in acute myocardial infarction. There is clear evidence that thrombolytic …

Acute myocardial infarction, the leading cause of death in western society, has been the
focus of more randomized clinical trial effort over the past decade than any other area of …

Pharmacotherapy for acute myocardial infarction (AMI) encompasses many therapeutic
areas, including treatment of the event itself and its possible complications …

Background: There is conclusive evidence from large scale randomized clinical trials (RCTs)
that several treatments administered in the acute phase of a myocardial infarction (AMI) …

In the February 1993 issue of Current Problems in Cardiology, Drs. Guy Reeder and
Bernard Gersh presented an excellent discussion on the Modern Management of Acute …

The results of recent randomized clinical trials performed in patients with acute ST elevation
myocardial infarction suggest that the short-term mortality of these patients is around 5–6 …

At the dawn of the next millennium, the optimal management of acute myocardial infarction
will have been defined by multiple clinical trials of acute reperfusion strategies, in …

Abstract The recently published American College of Cardiology/American Heart
Association Guidelines for the Management of Patients with Acute Myocardial Infarction …